deferasirox has been researched along with oseltamivir in 2 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (oseltamivir) | Trials (oseltamivir) | Recent Studies (post-2010) (oseltamivir) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 3,368 | 186 | 2,014 |
| Protein | Taxonomy | deferasirox (IC50) | oseltamivir (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.1104 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.2616 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 2.0317 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 1.1344 | |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | 0.002 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.005 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.008 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0003 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.003 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for deferasirox and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for deferasirox and oseltamivir
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |